An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...
Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...
Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...
Amgen's study of the drug Maritide in people with Type 2 diabetes showed noteworthy reductions in HbA1c and weight. The ...
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...
Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
As Novo Nordisk launches first FDA-approved oral weight loss medication, independent examination evaluates Ro's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback